Amgen Scoffs At Roche Proposal In EPO Patent Battle
Amgen Inc. reiterated its desire for a permanent injunction barring F. Hoffman-La Roche Ltd.'s anemia treatment Mircera from the U.S. market, in response to the Swiss company's proposal to make the...To view the full article, register now.
Already a subscriber? Click here to view full article